Stock Analysis

Capital Allocation Trends At Boule Diagnostics (STO:BOUL) Aren't Ideal

What are the early trends we should look for to identify a stock that could multiply in value over the long term? Firstly, we'll want to see a proven return on capital employed (ROCE) that is increasing, and secondly, an expanding base of capital employed. Ultimately, this demonstrates that it's a business that is reinvesting profits at increasing rates of return. However, after investigating Boule Diagnostics (STO:BOUL), we don't think it's current trends fit the mold of a multi-bagger.

Advertisement

What Is Return On Capital Employed (ROCE)?

For those who don't know, ROCE is a measure of a company's yearly pre-tax profit (its return), relative to the capital employed in the business. To calculate this metric for Boule Diagnostics, this is the formula:

Return on Capital Employed = Earnings Before Interest and Tax (EBIT) ÷ (Total Assets - Current Liabilities)

0.069 = kr40m ÷ (kr803m - kr229m) (Based on the trailing twelve months to June 2024).

Thus, Boule Diagnostics has an ROCE of 6.9%. Ultimately, that's a low return and it under-performs the Medical Equipment industry average of 9.3%.

See our latest analysis for Boule Diagnostics

roce
OM:BOUL Return on Capital Employed July 24th 2024

Above you can see how the current ROCE for Boule Diagnostics compares to its prior returns on capital, but there's only so much you can tell from the past. If you'd like, you can check out the forecasts from the analysts covering Boule Diagnostics for free.

What The Trend Of ROCE Can Tell Us

When we looked at the ROCE trend at Boule Diagnostics, we didn't gain much confidence. Over the last five years, returns on capital have decreased to 6.9% from 9.9% five years ago. Meanwhile, the business is utilizing more capital but this hasn't moved the needle much in terms of sales in the past 12 months, so this could reflect longer term investments. It's worth keeping an eye on the company's earnings from here on to see if these investments do end up contributing to the bottom line.

The Bottom Line

Bringing it all together, while we're somewhat encouraged by Boule Diagnostics' reinvestment in its own business, we're aware that returns are shrinking. And investors may be expecting the fundamentals to get a lot worse because the stock has crashed 72% over the last five years. All in all, the inherent trends aren't typical of multi-baggers, so if that's what you're after, we think you might have more luck elsewhere.

If you'd like to know about the risks facing Boule Diagnostics, we've discovered 1 warning sign that you should be aware of.

While Boule Diagnostics isn't earning the highest return, check out this free list of companies that are earning high returns on equity with solid balance sheets.

Valuation is complex, but we're here to simplify it.

Discover if Boule Diagnostics might be undervalued or overvalued with our detailed analysis, featuring fair value estimates, potential risks, dividends, insider trades, and its financial condition.

Access Free Analysis

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

About OM:BOUL

Boule Diagnostics

Develops, manufactures, and markets instruments and consumable products for blood diagnostics in the United States of America, Asia, Eastern Europe, Latin America, Western Europe, Africa, and the Middle East.

Undervalued with reasonable growth potential.

Advertisement

Updated Narratives

CO
ASTOR logo
composite32 on Astor Enerji ·

Astor Enerji will surge with a fair value of $140.43 in the next 3 years

Fair Value:₺140.4335.5% undervalued
1 users have followed this narrative
0 users have commented on this narrative
0 users have liked this narrative
RE
PROX logo
RecMag on Proximus ·

Proximus: The State-Backed Backup Plan with 7% Gross Yield and 15% Currency Upside.

Fair Value:€17.1356.7% undervalued
30 users have followed this narrative
0 users have commented on this narrative
0 users have liked this narrative
AG
Agricola
IPT logo
Agricola on IMPACT Silver ·

A case for for IMPACT Silver Corp (TSXV:IPT) to reach USD $4.52 (CAD $6.16) in 2026 (23 bagger in 1 year) and USD $5.76 (CAD $7.89) by 2030

Fair Value:CA$7.8996.2% undervalued
1 users have followed this narrative
0 users have commented on this narrative
0 users have liked this narrative

Popular Narratives

TH
TheWallstreetKing
MVIS logo
TheWallstreetKing on MicroVision ·

MicroVision will explode future revenue by 380.37% with a vision towards success

Fair Value:US$6098.4% undervalued
101 users have followed this narrative
10 users have commented on this narrative
20 users have liked this narrative
AN
AnalystConsensusTarget
NVDA logo
AnalystConsensusTarget on NVIDIA ·

NVDA: Expanding AI Demand Will Drive Major Data Center Investments Through 2026

Fair Value:US$250.3929.3% undervalued
932 users have followed this narrative
6 users have commented on this narrative
23 users have liked this narrative
OS
oscargarcia
GOOGL logo
oscargarcia on Alphabet ·

The company that turned a verb into a global necessity and basically runs the modern internet, digital ads, smartphones, maps, and AI.

Fair Value:US$3405.8% undervalued
140 users have followed this narrative
6 users have commented on this narrative
18 users have liked this narrative